10-Q: Xencor Reports Q1 2025 Financial Results and Provides Business Update

Xencor, Inc. announces its financial results for the first quarter of 2025, highlighting revenue growth and progress in its clinical-stage biopharmaceutical programs.

Summary

• Xencor, Inc. reported a net loss attributable to Xencor, Inc. of $48.4 million, or $0.66 per share, for the three months ended March 31, 2025.
• This compares to a net loss of $73.4 million, or $1.20 per share, for the same period in 2024.
• Total revenue for Q1 2025 was $32.7 million, up from $16.0 million in Q1 2024, driven by collaboration, milestone, and royalty revenues.
• Research and development expenses increased slightly to $58.6 million from $56.9 million year-over-year.
• General and administrative expenses also rose to $17.3 million from $13.8 million in the prior year.
• The company's cash, cash equivalents, and marketable securities totaled $693.5 million as of March 31, 2025.
• Xencor is advancing multiple drug candidates into clinical development, including XmAb819, XmAb541, and XmAb942.
• Two additional drug candidates, plamotamab and XmAb657, are planned to enter clinical development in 2025.
• The company is also involved in legal proceedings with Merus N.V. regarding patent infringement claims.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, revenue is up and there is progress in the clinical pipeline. However, the identified material weaknesses in internal controls and the ongoing legal proceedings are causes for concern.

Positives

• Revenue increased significantly year-over-year, driven by milestone payments and royalties.
• The company has a strong cash position to fund ongoing and planned clinical trials.
• Multiple drug candidates are progressing through clinical development, with new studies planned for 2025.
• Xencor received a $12.5 million regulatory milestone payment from Incyte.
• Vir Bio initiated a Phase 3 study for tobevibart, triggering a $2.0 million milestone payment to the Company.

Negatives

• The company continues to operate at a net loss, although the loss decreased compared to the prior year.
• General and administrative expenses increased.
• The company recorded asset impairment charges of $4.9 million during the three months ended March 31, 2025, related to its decision in the first quarter of 2025 to pause further development of certain programs and prioritize resources toward advancing other pipeline programs.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level due to the material weakness related to the design of controls related to its review of the accounting treatment of the proceeds from the sale of future royalties pursuant to the Ultomiris Royalty Sale Agreement as part of non-routine transactions and the design of controls related to the evaluation of certain tax legislation.

Risks

• The company is involved in ongoing legal proceedings with Merus N.V. regarding patent infringement.
• The company acknowledges material weaknesses in its internal control over financial reporting.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company's success depends on its ability to attract and retain key personnel.
• Unfavorable global economic or political conditions could adversely affect the company's business, financial condition or results of operations.
• Disruptions at the FDA and other government agencies caused by changing priorities or funding shortages could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

Future Outlook

Xencor expects to continue advancing its clinical programs and plans to initiate new clinical studies for plamotamab and XmAb657 in 2025. The company believes its current financial resources are sufficient to fund operations through at least the next twelve months.

Management Comments

• Management is committed to maintaining a strong internal control environment.
• Management intends to implement comprehensive remediation actions in a timely manner, under the appropriate oversight of the Audit Committee.

Industry Context

Xencor operates in the competitive biopharmaceutical industry, focusing on engineered antibody therapeutics. The company's partnerships and licensing agreements are common strategies for biotech firms to leverage their technologies and drug candidates. The progress of XmAb-based drugs like Monjuvi and Ultomiris, developed with partners, highlights the potential of Xencor's technology.

Comparison to Industry Standards

• Xencor's approach to protein engineering, particularly its XmAb platform, is comparable to other companies specializing in antibody engineering, such as Regeneron and Genmab.
• The company's strategy of out-licensing certain assets while retaining rights to others is similar to that of companies like BioNTech, which partners with larger pharmaceutical firms to develop and commercialize its technologies.
• The reported cash position is relatively strong for a clinical-stage company, providing runway for ongoing and planned clinical trials, similar to companies like CRISPR Therapeutics that have significant cash reserves to support their research and development efforts.
• The legal proceedings with Merus N.V. are not uncommon in the biopharmaceutical industry, where intellectual property is highly valuable and often contested, similar to patent disputes involving companies like Amgen and AbbVie.

Management Changes

Legal Proceedings

• Xencor is currently a party to an action initiated by Merus N.V. alleging patent infringement.

Stakeholder Impact

• Shareholders: The financial results and clinical progress will impact shareholder value.
• Employees: The company's financial stability and pipeline progress affect job security and opportunities.
• Patients: The development of new therapies has the potential to improve treatment options for various diseases.
• Collaborators: Partnerships and licensing agreements are crucial for revenue generation and drug development.

Next Steps

• Initiate a Phase 2b study of XmAb942 in ulcerative colitis (XENITH-UC Study) in the second half of 2025.
• Initiate a Phase 1b/2a proof-of-concept study for plamotamab in rheumatoid arthritis in the first half of 2025.
• Initiate a first-in-human study for XmAb657 during the second half of 2025.
• Continue lead selection studies and GMP production campaigns for a TL1A x IL-23p19 bispecific antibody, with first-in-human studies anticipated during 2026.

Key Dates

Keywords

Xencor, financial results, clinical trials, biopharmaceutical, antibody therapeutics, XmAb, milestone payments, royalties, oncology, autoimmune diseases